Ideal drug or dead-end molecule?

Are you ready to move to transient protein expression? On the surface, an antibody molecule can look like an ideal candidate but what if you looked a little closer?

In-depth characterization is a vital stage in scaling up your molecule for transient protein expression and ultimately stable cell line development.

Spending time on a transient protein expression pilot program can help you rule out dead-end molecules and avoid nasty surprises at a later stage.

5 top tips for a transient protein expression pilot

Think you know your molecule?

Having the ability to distinguish an ideal drug candidate from a dead-end molecule at this stage is an absolute must for a successful drug developer.

In this  example, the presence of multimers and aggregates, only identified by a more thorough analysis, skew the affinity results and mask a low quality preparation of antibody.

Deep analysis of function, purity and protein quality is therefore vital.

About Fusion Antibodies

We are world leaders in antibody development services specializing in the discovery, engineering and supply of pre-clinical biologics to clinical Cell Line Development.

Fusion offers flexibility and agility while delivering clinical candidates focusing on developability, manufacturability and function.

Additional Reading

Sequencing image
Expert Insights

Stepping outside of the CDR to create naturalised libraries and humanized antibodies

With their high specificity, efficacy and safety profiles, it’s no wonder that antibodies have become the biggest selling drugs in recent years.
Antibody Fragment Image
Expert Insights

Humanized antibody innovation: Top tips for outsourcing

Dr Richard Buick, CTO of Fusion Antibodies explains what he believes to be the top criteria to consider when selecting a humanization outsourcing partner
Fusion Scientist in CLD Lab
Expert Insights

Starting your journey into manufacturing – choosing a cell line development provider

One of the biggest decisions which any company developing biological medicines makes is to move forward to the manufacture of their product.